MX2023009374A - Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib. - Google Patents

Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib.

Info

Publication number
MX2023009374A
MX2023009374A MX2023009374A MX2023009374A MX2023009374A MX 2023009374 A MX2023009374 A MX 2023009374A MX 2023009374 A MX2023009374 A MX 2023009374A MX 2023009374 A MX2023009374 A MX 2023009374A MX 2023009374 A MX2023009374 A MX 2023009374A
Authority
MX
Mexico
Prior art keywords
breast cancer
abemaciclib
ribociclib
gdc
combination therapies
Prior art date
Application number
MX2023009374A
Other languages
English (en)
Inventor
Xiaojing Wang
Ciara Metcalfe
Pablo Diego Perez-Moreno
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023009374A publication Critical patent/MX2023009374A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan tratamientos conjuntos que comprenden GDC-9545 y abemaciclib o ribociclib para tratar cáncer de mama localmente avanzado o cáncer de mama metastásico.
MX2023009374A 2021-02-16 2022-02-14 Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib. MX2023009374A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163149941P 2021-02-16 2021-02-16
PCT/US2022/016268 WO2022177843A1 (en) 2021-02-16 2022-02-14 Treatment of breast cancer using combination therapies comprising gdc-9545 and abemaciclib or ribociclib

Publications (1)

Publication Number Publication Date
MX2023009374A true MX2023009374A (es) 2023-08-16

Family

ID=80685250

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009374A MX2023009374A (es) 2021-02-16 2022-02-14 Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib.

Country Status (11)

Country Link
US (1) US20230381154A1 (es)
EP (1) EP4294394A1 (es)
JP (1) JP2024506348A (es)
KR (1) KR20230146523A (es)
CN (1) CN116887828A (es)
AU (1) AU2022222660A1 (es)
CA (1) CA3210479A1 (es)
IL (1) IL304911A (es)
MX (1) MX2023009374A (es)
TW (1) TWI828060B (es)
WO (1) WO2022177843A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170362228A1 (en) * 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
PL3810283T3 (pl) * 2018-06-21 2023-10-16 F. Hoffmann-La Roche Ag Postacie stałe soli winianowej 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropylo)azetydyn-3-ylo)amino)fenylo)-3-metylo-1,3,4,9-tetrahydro-2H-pirydo[3,4-b]indol-2-ilo)-2,2-difluoropropan-1-olu, sposób ich otrzymywania i sposoby ich zastosowania w leczeniu nowotworów
AU2019321588A1 (en) 2018-08-17 2021-03-04 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
EP4149476A1 (en) * 2020-05-12 2023-03-22 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor

Also Published As

Publication number Publication date
JP2024506348A (ja) 2024-02-13
TWI828060B (zh) 2024-01-01
EP4294394A1 (en) 2023-12-27
CN116887828A (zh) 2023-10-13
TW202239405A (zh) 2022-10-16
CA3210479A1 (en) 2022-08-25
KR20230146523A (ko) 2023-10-19
WO2022177843A1 (en) 2022-08-25
AU2022222660A9 (en) 2024-07-11
AU2022222660A1 (en) 2023-07-27
US20230381154A1 (en) 2023-11-30
IL304911A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
MX2018010261A (es) Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
MX2024002838A (es) Metodos para tratar trastornos usando inhibidores de csf1r.
MX2018006831A (es) Metodos de tratamiento de neoplasias malignas.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX2016004489A (es) Sistemas y metodos para tratar el cancer y/o aumentar la funcion de organos.
MX2022007678A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
IL188101A0 (en) Use of hif 1-alpha modulators for treatment of cancer
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.
MX2022014133A (es) Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6.
MX2023008193A (es) Procedimientos para tratar el cáncer.
IL307964A (en) Combined treatment for cancer
MX2023007680A (es) Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina.
MX2024004171A (es) Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2021003262A (es) Metodos de tratamiento.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2023009374A (es) Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib.
MX2020013883A (es) Tratamientos oncológicos con agentes de zinc.
MX2021003265A (es) Metodos de tratamiento.
MX2023003034A (es) Metodos, terapias y usos para tratar el cancer.
IL288178A (en) Combined gmci and ddri treatment for cancer